首页> 外文期刊>Andrology >Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy
【24h】

Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy

机译:预处理前列腺组织雄激素含量对原发性雄激素剥夺治疗患者去势抵抗性前列腺癌发展预测的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Great advances in tissue androgen analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) have made it possible to evaluate the tissue androgen content from a single needle prostate biopsy specimen. In this study, we investigated if pre-treatment androgen content in prostate biopsy specimens could predict their response to primary androgen deprivation therapy (ADT) and future castration-resistant prostate cancer (CRPC). One-hundred and sixty-five prostate cancer patients who received primary ADT were enrolled. They had received multiple core prostate needle biopsy at diagnosis, and an additional one needle biopsy specimen was obtained for tissue androgen determination using LC-MS/MS. The patients' prostate specific antigen (PSA) values were periodically followed during the treatment and patients were determined to have CRPC when their PSA value increased continuously to 25% above the nadir and a 2.0ng/mL increase. A significant correlation was found between PSA value decline velocity (PSA half-time) after ADT and pre-ADT tissue androgen content. Twenty-three patients were determined to have CRPC. These CRPC patients had a significantly high concentration of tissue T (p<0.01) and low concentration of tissue 5-dihydrotestosterone (DHT) (p<0.01), resulting in a higher tissue T/DHT ratio (p<0.001). A multivariate Cox proportional hazard model revealed the pre-ADT tissue T/DHT ratio and Gleason score as independent predictors for CRPC development. By using the two statistically significant variables, the relative risk of CRPC development could be calculated. The results of this study suggest that the evaluation of prostate androgen content in a single needle biopsy specimen may be useful to predict future CRPC development after primary ADT. Further studies are required for the clinical application of T/DHT ratio evaluation.
机译:使用液相色谱-串联质谱(LC-MS / MS)进行组织雄激素分析的重大进展使得评估单针前列腺活检标本中的组织雄激素含量成为可能。在这项研究中,我们调查了前列腺活检标本中的雄激素含量是否可以预测其对原发雄激素剥夺疗法(ADT)和未来去势抵抗性前列腺癌(CRPC)的反应。纳入接受原发性ADT的165例前列腺癌患者。他们在诊断时接受了多核心前列腺穿刺活检,并获得了另外一个穿刺活检标本,用于使用LC-MS / MS测定组织雄激素。在治疗过程中定期跟踪患者的前列腺特异性抗原(PSA)值,当患者的PSA值连续增加至最低点以上25%并且增加2.0ng / mL时,确定患者患有CRPC。发现ADT后PSA值下降速度(PSA半时间)与ADT前组织雄激素含量之间存在显着相关性。确定23例患有CRPC。这些CRPC患者的组织T浓度显着较高(p <0.01),而组织5-二氢睾丸激素(DHT)的浓度较低(p <0.01),从而导致组织T / DHT比率较高(p <0.001)。多元Cox比例风险模型显示ADT之前的组织T / DHT比率和Gleason评分是CRPC发展的独立预测因子。通过使用两个统计上显着的变量,可以计算出CRPC发展的相对风险。这项研究的结果表明,对单针活检标本中前列腺雄激素含量的评估可能有助于预测原发性ADT后CRPC的未来发展。 T / DHT比评估的临床应用需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号